Estrogen dominance is now a growing health concern for both men and women. Myomin helps the body metabolize unhealthy estrogens and remove conditions like endometriosis, ovarian cysts and uterine fibroids in women and prostate enlargement and low libido in men.
Estrogen receptors are found in almost every tissue in the body. When estrogen is released, it passes directly into cells throughout the body, binds to receptors, and initiates cell activity. Because estrogen encourages protein production and cell division, it is vital to your growth not just during puberty but in adult life.
Estrogen triggers cell division but excess estrogen can promote abnormal cell division and growth of estrogen-responsive tissues. This can create an environment suitable for many estrogen dominant disorders. Long-term exposure to exogenous hormones, such as in hormone replacement therapy, is another major factor of estrogen dominance.
Among women, excessive estrogen can either cause or exacerbate conditions like cysts, fibroids, endometriosis, fibrocystic breasts and cancer in the reproductive organs.In men, prostate enlargement, low libido and even prostate cancer are associated with estrogen dominance. For both men and women, high estrogen level contributes toward obesity, insulin resistance, cardiovascular risk and autoimmune diseases, to name a few.
The biggest factor causing an increase in estrogen dominant men and women is environmental hormones, or xenoestrogens. These contribute to estrogen dominance by mimicking the effects of estrogen and they are in almost everything we come in contact with and even eat. Xenoestrogens include plasticizers, pesticides, clouding agents in drinks, phthalates, and heavy metals. Myomin is able to control the excessive conversion of other hormones into estrogen. As a result, optimal levels of progesterone, testosterone and estrogen are achieved.
Estrogen dominant conditions for women include cysts, fibroids, endometriosis, fibrocystic breasts, reproductive organ cancer, obesity, diabetes, insulin resistance, cardiovascular risk, and autoimmune conditions. Estrogen dominant conditions for men include enlarged prostate, prostate cancer, low libido, obesity, diabetes, insulin resistance, cardio vascular risk, and autoimmune conditions.
Treatment of these disorders involves blocking the action of estrogen of the affected tissues. Myomin is also a natural remedy for cysts, tumors, fibroids, prostate issues, estrogen dominance and other hormonal issues.
As men age, testosterone is being more readily converted to estrogen through the aromatase enzyme. Increased estrogen levels can lead to problems such as prostate cancer, prostatitis, and even gynecomastia.Evidence also shows that high estrogen levels in men causes abnormalities, especially in the prostate. In men, estrogen is primarily synthesized in fat tissue. This is why men with metabolic conditions, like diabetes, usually exhibit high estrogen levels. Some abnormalities that can result include low sperm count/quality and decreased testosterone levels. There is also some proof that fetal exposure to environmental estrogens increases incidence of testicular cancer.
Myomin was first marketed for its clinical effects on uterine fibroids, fibrocystic breasts and ovarian cysts. Further studies later revealed that Myomin reduced estradiol level, which explained its effect on the above conditions. A few years later, more studies found that the underlying mechanism for its estradiol reduction function is aromatase reduction. Aromatase is the enzyme that converts androgens, or male hormones, into estrogens, particularly estrone and estradiol.
Myomin's aromatase reduction mechanism allows it to be effective in estrogen-dominant conditions affecting pre- and postmenopausal women as well as men. In the last Chi Health Letter, we presented Myomin's normalizing effect on testosterone due to this mechanism.
Myomin contains Aralia, Smilax glabra, Curcurma zedoria, and Cyperus rotundus. These herbs have been traditionally used for various female ailments and hormone related disorders. Aralia and Cyperus rotundus both can reduce estradiol. Cyperus is also effective against cervical endometriosis and cervical carcinoma. Additionally, Aralia has been found to be cytotoxic against several human cancer cell lines. Aromatase is a key enzyme in the synthesis of estrogen. Specifically, it converts androstenedione into estrone and testosterone into estradiol. Evidence shows that breast cancer and prostate cancer tissues overexpress aromatase. Inhibiting aromatase, therefore, plays an important role in suppressing the deleterious action of estrogen on hormone related conditions.
Myomin has also been reported to be effective in reducing the severity and frequency of hot flashes in some women. Although its exact mechanism on this particular function remains to be elucidated, it may be explained by Myomin's ability to compete with estrogen at the cells' estrogen receptors. It should be noted, however, that some women experience worsening of symptoms with Myomin. This is probably due to very low levels of estrogen in these women.
Myomin Reduces Estradiol in Postmenopausal Female
In one case, F. Cromeyer, a pharmacist from Texas, share that a postmenopausal female patient took Myomin for 2 months. Her estradiol started at 6.5 pg/ml and was effectively reduced to 2.4 pg/ml, well within the normal range. Contrary to common belief, it is possible to have a high estradiol level after menopause, as illustrated in this case. Hormone replacement therapy, xenoestrogens and obesity are just some of the few factors that contribute towards estrogen increase.
Myomin reduces estradiol in Postmenopausal Female with Fibrocystic Breasts and Breast Cancer History
Y. Dikansky, ND from New York, has a 48-year-old postmenopausal female patient who had breast cancer at age 39 and age 43. In May 2011, at 48 years old, she found that she had fibrocystic breasts and high estradiol (196.50 pg/ml). She started taking Myomin and five months later, her estradiol reduced to 53.21 pg/ml.
Myomin reduces Estradiol in Male Patient on Testosterone Therapy
Testosterone is converted to estradiol through the aromatase enzyme. So if an individual is on testosterone replacement therapy, its hyperaromatization is very likely, leading to increased estradiol, as in the following case. G. Adams, MD from Florida, has a male patient on testosterone therapy. Not surprisingly, his estradiol increased to 95 pg/ml. After adding Myomin for 5 months, his estradiol reduced to a normal 25 pg/ml.
The statements and products referred to throughout this site have not been evaluated by the FDA. They are the expressed opinion of John Gray for the sole purpose of educating the public regarding their health, happiness and improved quality of relationships. They are not intended to diagnose, treat, cure or prevent any disease. Individual results may vary. Seek the advice of a competent health care professional for your specific health concerns.